Immunological
1672, England — Thomas Willis, 'De Anima Brutorum'
Myasthenia gravis presented one of medicine's most intriguing diagnostic puzzles for several centuries, with historical physicians struggling to account for a pattern of muscular weakness that fluctuated in ways that defied the anatomical lesion-based thinking dominant in their era. The condition's history wound through neurology, physiology, and eventually immunology before its underlying mechanism was elucidated in the twentieth century. That journey involved some of the most creative experimental work in the history of medicine, connecting clinical observation to fundamental discoveries about how nerves communicate with muscles.
Historical Narrative
The earliest recognizable clinical descriptions of myasthenia gravis appeared in the seventeenth century, with Oxford physician Thomas Willis providing what is often cited as the first clear account in his 1672 work 'De Anima Brutorum.' Willis described patients with fluctuating weakness who were stronger in the morning and grew progressively weaker with exertion, and while he lacked any framework for understanding the underlying mechanism, his clinical observations were remarkably precise for their era. Willis attributed the condition to problems in the animal spirits, the theoretical medium through which seventeenth century physicians explained nervous function.
For the next two centuries, sporadic case reports appeared in the medical literature without coalescing into a recognized clinical entity. The German physician Wilhelm Erb published a significant case series in 1878, describing several patients with the characteristic pattern of fatiguable weakness, and the English physician Samuel Goldflam added important observations in 1893. The condition was briefly known as the Erb-Goldflam symptom complex in recognition of their contributions. It was the Polish-German neurologist Friedrich Jolly who in 1895 gave the condition the name myasthenia gravis pseudoparalytica, later shortened to myasthenia gravis, meaning severe muscle weakness, and who first described the characteristic electromyographic fatigability that would later become central to its investigation.
The first major therapeutic insight came through an accidental observation. In 1934, Scottish physician Mary Broadfoot Walker, working at St. Alfege's Hospital in London, reasoned that the pattern of muscular fatigability in myasthenia gravis resembled the effects of curare poisoning, for which physostigmine was then being studied as an antidote. Walker administered physostigmine to a patient with myasthenia gravis and observed a dramatic if temporary improvement. Walker's insight, published in The Lancet, transformed clinical management of the condition for decades and pointed toward the neuromuscular junction as the critical site of pathology, even though the mechanism remained unclear.
Research in the following decades focused on understanding the physiology of the neuromuscular junction itself. The discovery of acetylcholine as a neurotransmitter and the elucidation of its role in muscle contraction by Henry Dale and Otto Loewi, work for which they shared the Nobel Prize in 1936, provided the theoretical framework within which myasthenia gravis could eventually be understood. By the 1960s, electron microscopy was revealing structural abnormalities at the neuromuscular junction in affected patients.
The decisive immunological breakthrough came in the 1970s. Jon Lindstrom and colleagues discovered in 1973 that injecting animals with purified acetylcholine receptors produced a syndrome resembling myasthenia gravis, and researchers including Daniel Drachman, Andrew Engel, and others subsequently demonstrated that patients with the condition harbored antibodies directed against their own acetylcholine receptors. This established myasthenia gravis as an autoimmune condition, one of the first diseases for which a specific antibody-mediated attack on a known molecular target was clearly demonstrated. The historical significance of this finding extended far beyond the single disease, reshaping how medicine understood the immune system's capacity for self-directed pathology.
Key Historical Figures
Historical narrative only — this page describes how Myasthenia gravis was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.